Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CymaBay Therapeutics, Inc.
  6. Summary
    CBAY   US23257D1037

CYMABAY THERAPEUTICS, INC.

(CBAY)
  Report
Real-time Estimate Cboe BZX  -  05/27 03:31:19 pm EDT
2.010 USD   +2.03%
05/23CymaBay Therapeutics Says Seladelpar Reduces Need for Liver Transplants
MT
05/23CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
AQ
05/23CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
1.98(c) 1.91(c) 1.92(c) 1.97(c) 2 Last
405 546 447 302 568 783 331 401 228 517 Volume
-5.71% -3.54% +0.52% +2.60% +1.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 4,29 M - -
Net income 2022 -107 M - -
Net cash position 2022 38,8 M - -
P/E ratio 2022 -1,56x
Yield 2022 -
Sales 2023 7,86 M - -
Net income 2023 -120 M - -
Net cash position 2023 130 M - -
P/E ratio 2023 -1,48x
Yield 2023 -
Capitalization 163 M 163 M -
EV / Sales 2022 28,9x
EV / Sales 2023 4,13x
Nbr of Employees 59
Free-Float 95,6%
More Financials
Company
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in... 
Read more
More about the company
Ratings of CymaBay Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C+
More Ratings
All news about CYMABAY THERAPEUTICS, INC.
05/23CymaBay Therapeutics Says Seladelpar Reduces Need for Liver Transplants
MT
05/23CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients fo..
AQ
05/23CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patie..
CI
05/18B. Riley Lowers Cymabay Therapeutics' Price Target to $8 from $10 to Account for Slight..
MT
05/16HC Wainwright Lowers Cymabay Therapeutics's Price Target to $10 From $12, Maintains Buy..
MT
05/12Cymabay Therapeutics Q1 Loss Widens, Sees Enough Funds Through 2023 -- Stock Rises 7% A..
MT
05/12TRANSCRIPT : CymaBay Therapeutics, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12CYMABAY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/12CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update
AQ
05/12CymaBay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/12EARNINGS REACTION HISTORY : CymaBay Therapeutics Inc, 60.0% Follow-Through Indicator, 17.9..
MT
05/11CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022
AQ
05/05CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May..
AQ
04/19CYMABAY THERAPEUTICS, INC. Change in Directors or Principal Officers (form 8-K/A)
AQ
04/19CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nomina..
CI
More news
News in other languages on CYMABAY THERAPEUTICS, INC.
05/23Selon CymaBay Therapeutics, le Seladelpar réduit le besoin de transplantations hépatiqu..
05/23CymaBay Therapeutics, Inc. Présente de nouvelles conclusions selon lesquelles le traite..
05/12La perte de Cymabay Therapeutics au premier trimestre s'accentue, mais l'entreprise est..
05/12CymaBay Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 m..
05/12HISTORIQUE DES RÉACTIONS AUX BÉNÉFIC : CymaBay Therapeutics Inc, indicateur de suivi à 60,..
More news
Analyst Recommendations on CYMABAY THERAPEUTICS, INC.
More recommendations
Chart CYMABAY THERAPEUTICS, INC.
Duration : Period :
CymaBay Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYMABAY THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 1,92 $
Average target price 10,25 $
Spread / Average Target 434%
EPS Revisions
Managers and Directors
Sujal Shah President & Chief Executive Officer
Daniel Menold Controller
Robert James Wills Chairman
Charles A. McWherter Senior Vice President-Research
Dennis D. Kim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CYMABAY THERAPEUTICS, INC.-43.20%163
GILEAD SCIENCES, INC.-10.47%81 543
REGENERON PHARMACEUTICALS, INC.9.40%74 440
VERTEX PHARMACEUTICALS23.33%69 269
WUXI APPTEC CO., LTD.-25.70%39 423
BIONTECH SE-40.00%37 588